Abbott now has a total of six targets under investigation from the strategic collaboration established between Celera Genomics and Abbott to discover, develop and commercialize therapies for the treatment of cancer.
As part of the collaboration a number of protein antigens identified and validated by Celera Genomics are being screened by Abbott. The agreement encompasses the development of therapeutic antibodies and small molecule drugs against over-expressed cell-surface proteins that have been associated with cancer and identified as therapeutic targets through proteomics research at Celera Genomics.
Any of these antigens may be selected for therapeutic development at Abbott. Once this development is complete, Celera Genomics may elect to jointly fund clinical development and commercialization of any resulting therapeutic products and would share any financial returns resulting from commercialization, or alternately be paid milestones and royalties on successful therapies.
Abbott has responsibility for the commercialization of jointly funded collaboration products. Celera Genomics retains certain diagnostic rights associated with selected targets.